ANEXT, a Shanghai-based exosome specialist, has launched two clinical studies for their product ANEXT FIT CELL, which is derived from mesenchymal stem cells exosomes. One study aims to evaluate the product’s efficacy in treating cough symptoms following infection, while the other is focused on safety and preliminary efficacy in the acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD).
ANEXT FIT CELL is developed using ANEXT’s proprietary ANEXT Smart EX technology platform and is delivered through inhalation. This innovative approach allows the product to penetrate cell membranes and evade robust immune responses, ensuring the safe and effective delivery of therapeutic substances to compromised lung tissue. The product is poised to address the repair of organ damage induced by both COVID-19 and COPD.- Flcube.com
